Keywords: Pharming, Ruconest, Rhucin, Hereditary angioedema, HAE

Pharming’s Ruconest efficacy backed in new trial

Article | 24 May 2011

Netherlands-based biotechnology firm Pharming Group (NYSE Euronext: PHARM) says that new clinical data from open-label studies on its recombinant human ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Pharming

Go to company listing

Related Drugs

Ruconest

Rhucin

Go to drug listing